The Regional Blockbuster: When European Partners Shine
Executive Summary
Broadly speaking, Europe accounts for far less blockbuster drug revenue than the US, particularly in mass market categories where direct-to-consumer advertising is important. But Europe does provide its fair share of blockbuster sales in many areas that biotechs focus on, such as HIV, according to IMS Global Consulting.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.